Tango Therapeutics NASDAQ: TNGX said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for patients with MTAP-deleted metastatic pancreatic ductal adenocarcinoma, or PDAC.The company outlined the development plan after reporting updated early-stage clinical results for the combination ahead of a presentation at the European Society for Medical Oncology meeting. The data came from a Phase I dose-escalation s ...